The question now is not whether longevity science matters. The question is whether the United States intends to lead.

For decades, American researchers, entrepreneurs, physicians, and innovators have driven many of the breakthroughs that have transformed medicine. Yet, despite remarkable progress in our understanding of aging biology, public investment and national coordination have failed to keep pace with the opportunity before us.

The consequences of aging touch every American family. Cancer, Alzheimer's disease, cardiovascular disease, frailty, and countless other conditions impose immense human and economic costs. The science increasingly suggests that targeting the biological processes of aging itself would allow us to address many of these challenges simultaneously.

The nations that invest in longevity science today will help define the future of medicine tomorrow. By participating in this letter campaign, you urge your policymakers to recognize the significance of this moment and to treat longevity science as the strategic national priority it has become.